A Phase II Study of Hepalatide in Subjects With HBeAg-positive Chronic Hepatitis B
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect
Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects
with HBeAg-positive Chronic Hepatitis B